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Abstract
To assess the effectiveness of the treatment with high dosage of corticosteroids (CCSs), as ﬁrst-line therapy, in inducing remission in
naïve Adult-onset Still’s disease (AOSD) patients compared with low dosage of CCSs, after 6 months. To further evaluate the rate of
patients maintaining the remission and the rate of CCSs discontinuation, after additional 12 months of follow-up.
A retrospective evaluation of patients prospectively followed was designed to compare the rate of clinical remission in naïve AOSD
patients treated with high dosages of CCSs (0.8–1mg/kg/day of prednisone-equivalent) or low dosage of CCSs (0.2–0.3mg/kg/day
of prednisone-equivalent), after 6 months. An additional analysis was performed to compare the rate of monocyclic pattern between
these groups, after further 12 months of follow-up.
The clinical remission was achieved in a higher percentage of patients treated with the ﬁrst-line treatment with high dosage of CCSs
than treated the ﬁrst-line treatment with low dosage of CCSs. At the end of 18 months of follow-up, a larger percentage of patients
treated the ﬁrst-line treatment with high dosage of CCSs was classiﬁed as monocyclic pattern and discontinued CCSs when
compared with patients treated the ﬁrst-line treatment with low dosage of CCSs. Patients deﬁned as CCSs non-responder were
treated with methotrexate (MTX)+CCSs or with combination therapy CCSs+MTX+biologic drug. The clinical remission was observed
in a percentage of these patients.
We showed the effectiveness of the ﬁrst-line treatment with high dosage of CCSs in inducing clinical remission in naïve AOSD
patients when compared with the ﬁrst-line treatment with low dosage of CCSs. The ﬁrst-line treatment with high dosage of CCSswas
also associated with the achievement of monocyclic pattern and CCSs discontinuation, after 18 months of follow-up.
Abbreviations: AOSD = Adult-onset Still’s disease, CCSs = corticosteroids, CRP = C-reactive protein, ESR = erythrocyte
sedimentation rate, MAS = macrophage activation syndrome, MTX = methotrexate, sDMARD = synthetic drug modifying anti-
rheumatic drugs, TNFi = tumor necrosis factor inhibitor.
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Adult-onset Still’s disease (AOSD) is a rare, systemic, inﬂamma-
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1spiking fever, arthritis, and evanescent rash. AOSD patients are
affected by life-threatening complications, mainly macrophage
activation syndrome (MAS), inﬂuencing prognosis.[2–4] Although
the pathogenic mechanisms are not entirely elucidated yet, AOSD
is categorized as a complex multigenic autoinﬂammatory disease
at the “crossroad” between autoinﬂammatory and autoimmune
disorders.[1] During AOSD, laboratory tests reﬂect the systemic
inﬂammatory process and high levels of both erythrocyte
sedimentation rate (ESR) and C-reactive protein (CRP) are
observed.[1–4] Characteristically, ferritin levels are higher than
those observed in other autoimmune, inﬂammatory, infectious,
or neoplastic diseases.[5,6] Analyzing AOSD course, 3 different
clinical patterns of AOSD are identiﬁed:1.
2.monocyclic pattern, characterized by a systemic single episode;
polycyclic pattern, characterized by multiple ﬂares, alternating
with remissions;
chronic pattern, related to a persistently active disease with3.
associated polyarthritis.[7]
Usually, 30% of AOSD patients develop a monocyclic pattern,
30% a polycyclic pattern and 40% a chronic pattern.[8,9]
Concerning therapeutic strategy, despite the growing body of
evidence in AOSD management, the therapy is largely empirical
deriving from case series and lacking speciﬁc guidelines.[10–13]
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treatment when the systemic symptoms predominate.[12] Second-
line therapies, including synthetic disease modifying anti-rheumat-
ic drugs (sDMARD) and biologic agents, are administered after the
lack of clinical response to ﬁrst-line CCSs.[14,15] Despite these
therapies, a large percentage of patients experiences several ﬂares
with an evolution toward the chronic disease course.[9,11,15,16] In
fact, the optimal management of AOSD patients is not adequately
clariﬁed and the effect of ﬁrst-line therapies on long-term
outcomes, as observed in rheumatoid arthritis,[17–19] it is not fully
elucidated yet.
In this study, we aimed to assess the effectiveness of high
dosage of CCSs, as ﬁrst-line treatment, in inducing clinical
remission in naïve AOSD patients when compared with low
dosage of CCSs after 6 months. Furthermore, we aimed to
evaluate the rate of patients maintaining the remission after
further 12 months of follow-up and the rate of CCSs
discontinuation. Finally, we assessed additional endpoints, the
MAS occurrence and if the combination therapy with other
immunosuppressive drugs could increase the achievement of
remission in non-responder patients.2. Methods
2.1. Study design
We designed a retrospective evaluation of patients prospectively
followed to compare the rate of clinical remission in naïve AOSD
patients treatedwith high dosages of CCSs or lowdosage ofCCSs
after 6 months. Following this ﬁrst evaluation, we performed an
additional analysis to compare the rate ofmonocyclic pattern and
the rate of CCSs discontinuation in patients treated with high
dosages of CCSs or low dosage of CCSs, after further 12 months
of follow up. The local Ethics Committee approved the study
protocol (ASL1 Avezzano-Sulmona-L’Aquila, L’Aquila, Italy;
protocol number 0139815/16) and it was performed accordingTable 1
Baseline clinical characteristics of assessed AOSD patients.
Baseline clinical
characteristics
Assessed
patients n: 80
High d
CCS
Age, mean±SD 45.83±15.93 47.76
Female, n (%) 51 (63.75%) 28 (7
Clinical features
Fever, n (%) 80 (100%) 40 (1
Arthritis, n (%) 69 (86.25%) 33 (8
Splenomegaly, n (%) 59 (73.75%) 33 (8
Skin rash, n (%) 57 (71.25%) 30 (7
Myalgia, n (%) 41 (51.25%) 21 (5
Sore throat, n (%) 40 (50.00%) 17 (4
Lymph node, n (%) 37 (46.25%) 21 (5
Liver involvement, n (%) 35 (43.75%) 18 (4
Abdominal pain, n (%) 6 (7.50%) 3 (7
Pericarditis, n (%) 3 (3.75%) 2 (5
Pleuritis, n (%) 3 (3.75%) 1 (2
Systemic score, mean±SD 5.10±1.50 5.06
Laboratory parameters
Leucocytosis, n (%) 59 (73.75%) 29 (7
Ferritin ng/mL, mean±SD 2544.73±367.34 2556.41
ESR (mm/hr), mean±SD 61.11±26.58 70.12
CRP (mg/L), mean±SD 77.34±38.68 80.82
Statistical signiﬁcance was expressed by a P value <.05. AOSD= adult onset Still’s disease; CCSs=c
2to the good clinical practice guidelines and declaration of
Helsinki. Informed consent was obtained from each patient for
the use of clinical and laboratory data for study purposes. In
reporting the results, we followed the STROBE checklist
(Additional Table 1).2.2. Patients eligibility criteria
Consecutive naïve AOSD patients, who were visited at the
recruiting centers, were assessed to be analyzed into the study. To
be assessed in the study, all AOSD patients had to fulﬁll the
following inclusion criteria:
[20]1.
2.osa
s n:
±1
0.0
00%
2.5
2.5
5.0
2.5
2.5
2.5
5.0
.50
.00
.50
±1
2.5
±6
±2
±3
orticdiagnostic criteria proposed by Yamaguchi;
naïve patients for high dosage of CCSs, sDMARD(s) and
biologic drugs, at the time of diagnosis;
at least 3 visits to be analyzed (baseline, after 6 and 183.
months).
Exclusion criteria were:1. use of higher dosage of CCSs than 10mg/day of prednisone
before study evaluation;
use of sDMARDs and any biologic drug before study2.
evaluation;
life-threating AOSD manifestations, at the time of diagnosis,3.
requiring, that is, high dosage CCSs and/or cytotoxic drugs.
2.3. Settings and locations
This study was designed as retrospective analysis of patients
prospectively followed, involving Rheumatologic Clinics at
University of L’Aquila and University of Palermo, with extensive
experience in AOSD diagnosis and management.[21,22] Consecu-
tive AOSD patients, between January 2001 and December 2017,
were evaluated and, if eligible according to aforementioned
criteria, were included in the analysis.ge of
40
Low dosage of
CCSs n: 40
High dosage versus
low dosage P values
5.86 43.55±15.97 .29
0%) 23 (57.50%) .66
) 40 (100%) 1.00
0%) 36 (90.00%) .20
0%) 26 (65.00%) .52
0%) 27 (67.50%) .79
0%) 20 (50.00%) .57
0%) 23 (57.50%) .06
0%) 15 (37.50%) .08
0%) 16 (40.00%) .26
%) 3 (7.50%) .22
%) 1 (2.50%) .12
%) 2 (5.00%) .18
.14 5.14±1.66 .83
0%) 30 (75.00%) .41
08.50 2800.48±799.17 .35
2.82 60.55±27.15 .30
4.71 75.16±31.47 .08
osteroids; ESR=erythrocyte sedimentation rate; CRP=C reactive protein; n=number.
Ruscitti et al. Medicine (2019) 98:15 www.md-journal.com2.4. Clinical management
During the clinical work-up before the diagnosis, NSAIDs and oral
CCSs at low dosages (10mg/daily of prednisone-equivalent[23])
were considered to be not-meaningful for the subsequent analyses.
During the ﬁrst phase of the evaluation, at the time of diagnosis,
patients treated with CCSs at the dosage of 0.8 to 1mg/kg/day of
prednisone-equivalent (high dosage of CCSs) were included in this
work. As comparator group, gender- and age-matched patients
treated, at the time of diagnosis, with CCSs at the dosage of 0.2 to
0.3mg/kg/day of prednisone-equivalent (low dosage of CCSs) were
accurately selected and included in the analysis. All the patients
included in theanalysis didnotpresent life-threatingmanifestations,
deﬁned according to available literature,[2] and the treatment with
high dosage CCSs or low dosage CCSswas administered according
to clinical judgment. In this retrospective evaluation, we recorded
these data from the clinical chart of each patient thus designing a
historical cohort study comparing 2 groups of AOSDpatients, who
were prospectively followed and treated with high dosage of CCSs
or with low dosage of CCSs. If AOSD-complications occurred,
patients were treated with iv high dosages of CCSs and cytotoxic
drugs as rescue therapy,[22] the rate of patients who experienced
complications was also assessed. Any increase of CCSs dosages to
maintain clinical responsewas considered to be a ﬂare of the disease
identifying non-responder patients, whowere consequently treated
with sDMARD and/or biologic drugs, as suggested by available
literature.[24] Speciﬁcally, the rates of patients treated with
methotrexate (MTX) and treated with biologic drugs, anakinra,
tumor necrosis factor inhibitor (TNFi) or tocilizumab, were
registered. Furthermore, according to clinical judgment and
patient’s clinical picture, patients could be treated with the
administration of medications to prevent the occurrence of
predictable CCSs side effects (i.e., bisphosphonates for CCSs-
induced osteoporosis) and/or the administration of prophylaxis for
opportunistic infections.We did not record these therapies because
considered to be not-meaningful for the analysis of study endpoints.
2.5. Endpoints
The primary endpoint of this study was the clinical remission in
naïve AOSD patients, after 6 months of follow-up from the
beginning. Clinical remission was deﬁned as the absence of joint,
systemic and laboratory evidence of disease activity, for at least 2
consecutive months, regardless of the initial therapeutic strategy,
following the available literature.[25] AOSD ﬂare was deﬁned as
the occurrence of systemic or joint features occurring after
remission or the need of any additional treatment and/or any
increase of medications dosage. Patient experiencing disease ﬂare
was deﬁned as non-responder. The secondary endpoints were the
percentage of patients maintaining the clinical remission, thus
achieving the monocyclic pattern and the rate of CCSs
discontinuation, after further 12 months of follow-up. According
to the disease course, at the end of this phase, after 18 months of
follow-up from the beginning, patients were categorized into 4
groups as described by Cush JJ et al[7]: 3 clinical patterns
(monocyclic, polycyclic, and chronic) and death, whichever the
course. A monocyclic course was deﬁned as a single episode for
more than 2 months but less than 1 year followed by sustained
remission through the entire follow-up period. A polycyclic
course was deﬁned as recurrent systemic ﬂares with remission
between ﬂares. A chronic course was deﬁned as at least a single
episode of persistent symptoms lasting longer than 1 year. AOSD-
related death was deﬁned as death correlated with the disease
during the follow-up. Finally, a number of additional endpoints3were assessed evaluating the percentage of patients discontinuing
CCSs, the MAS occurrence, the achievement of remission in non-
responder patients treated by CCSs+MTX or CCSs+MTX
+biologic drugs. The discontinuation of CCSs was deﬁned as
the withdrawal of CCSs, regardless the initial dosage, during the
follow-up. During ﬁrst and second phases of the study, each
patient was investigated, where appropriate, for MAS develop-
ment, which was deﬁned following the diagnostic criteria
proposed by the Histiocyte Society.[26] The achievement of
clinical remission in non-responder patients was deﬁned as the
percentage of patients achieving the primary endpoint with CCSs
+MTX or CCSs+MTX+biologic drugs, after lack of response
with ﬁrst line CCSs.2.6. Clinical assessment and data sources
The assessment at baseline ﬁrst included the exclusion of potential
mimickers, including infections, cancers, and other autoimmune or
autoinﬂammatory diseases, as previously detailed.[21,22] Brieﬂy,
blood tests and cultures, chest X-rays, abdominal echographywere
performed in all patients. Despite these exams, in the case of further
suspicionofmalignancy,weusedCTand/or PET/CTexams,where
appropriate bone marrow examination and lymph node biopsy
were performed. After that, the presence of the following clinical
features, at baseline, were recorded to assess the systemic
score:[21,27] fever, typical skin rash, arthralgia or arthritis, myalgia,
lymphadenopathy, sore throat, splenomegaly, hepatomegaly or
abnormal liver function tests, abdominal pain, sore throat, weight
loss, and gastrointestinal symptoms. The diagnosis of pleural
effusion or pleuritis and lung parenchymal involvement was made
by a chest radiographorCTscan, patientswith clinical suspicion of
pericarditis also underwent echocardiography. In addition, at
baseline and during the follow-up, each patientwas assessed for the
presence of AOSD-related complications. After 6months of follow
up, patients were assessed for achievement of clinical remission
according to pre-speciﬁed criteria. After 18 months of follow-up
frombaseline, patientswerenewlyassessed and stratiﬁed according
to above mentioned disease patterns. During the study, the
percentage of patients discontinuing CCSs, the MAS occurrence,
the achievement of remission in non-responder patients treated by
CCSs+MTX or CCSs+MTX+biologic drugs were assessed.2.7. Sample size estimation
Despite the retrospective nature of our study, we calculated the
sample size in order to maintain a conservative estimation on the
basis of previous studies reporting the effectiveness of CCSs in
AOSD. According to available information about high CCSs
dosages and effectiveness in AOSD patients,[12] we expected
remission percentage rates of 62.5% in patients treated with high
CCSs dosages and of 29.4% in patients treated with low CCSs
dosages. According to these expectations, we have provided the
following sample size estimation for 2-sample comparison of
proportions:1. test Ho: p1=p2, where p1 is the proportion in population 1
and p2 is the proportion in population 2;
assumptions: alpha=0.05 (2-sided); power=0.80; p1=0.625;2.
p2=0.294; n2/n1=1.00;
estimated required sample sizes: n1=34; n2=34.3.This sample size was estimated choosing a type I error level
(alpha) of 5% and a power (1-beta) of 80%. This choice was
suggested by the clinical concern of reaching an adequate sample
Table 2
Primary, secondary, and additional endpoints in assessed AOSD patients.
Primary and secondary endpoints Assessed
patients n: 73
High dosage of
CCSs n: 38
Low dosage of
CCSs n: 35
High dosage versus
low dosage P values
Primary Endpoint
Remission after 6 months, n (%) 33 (45.20%) 25 (64.79%) 8 (22.85%) <.001
Secondary Endpoint
Monocyclic pattern after 18 months, n (%) 20 (27.39%) 17 (44.73%) 3 (8.57%) .001
CCSs discontinuation after 18 months, n (%) 16 (21.91%) 13 (34.21%) 3 (8.57%) .03
Additional Endpoint
MAS occurrence, n (%)
∗
5 (6.25%) 1 (2.50%) 4 (10.00%) .16
Bolded values indicate statistically signiﬁcant results. Statistical signiﬁcance was expressed by a P value <.05. AOSD=adult onset Still’s disease; CCSs= corticosteroids; sDMARD(s)= synthetic disease-
modyfying antirheumatic drug(s); MAS=macrophage activation syndrome; n=number.
∗
Analysed on initial assessed patients, 4 patients developed MAS in the low dosage of CCSs group and were treated with i.v. CCSs and cytotoxic drugs.
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study, we included in our evaluation 40 patients in each arm to
minimize the missing data in endpoints.2.8. Statistical analysis
Data generated from our study were analyzed adjusting for the
longitudinal design. Due to the relatively simple design of the study,
we had a very low percentage of missing data, these values, which
were meaningful for analysis, were removed. Continuous variables
were normally-distributed and were expressed as mean± standard
deviation (SD). To compare the clinical characteristics between
groups of patients, the t test was used for all the continuous
variables, the Chi square test was used for all the categorical
variables. The statistical analysis of primary endpoint was planned
considering that primary response variable was discretely distrib-
uted (“yes clinical remission”/”no clinical remission”). Cox
regression analyses were thus performed assessing the statistical
signiﬁcance of the ﬁrst-line treatment with high dosage of CCSs on
the likelihood of the achievement of clinical remission after 6
months from the baseline. After univariate analysis, multivariate
model was built adjusting for multiple features considered to be
clinically relevant in primary endpoint achievement. The analysis of
secondary endpointswas similarlyperformed considering that these
variables were discretely distributed (“yesmonocyclic pattern”/”no
monocyclic pattern”; “yes CCSs discontinuation”/”no CCSs
discontinuation”). Cox regression analyses were thus performed
assessing the statistical signiﬁcance of the ﬁrst-line treatment with
high dosage of CCSs on the likelihood of the achievement of
monocyclic pattern and on the likelihood of the achievement of
CCSs discontinuation after 18 months from the baseline. Multi-
collinearity between independent variables was evaluated by using
the variance inﬂation factor (VIF) before entering each value in the
regression model. After excluding collinearity, independent
variables were added into the models. Additional endpoints were
also investigated and compared between the 2 groups. Two-sided P
values <.05 were considered statistically signiﬁcant. The Statistics
Package for Social Sciences (SPSS forWindows, version 17.0, SPSS
Inc., Chicago, IL) was used for all analyses.3. Results
3.1. Baseline characteristics
In this study, 80 patients were included and treated with high
dosage of CCSs or low dosage of CCSs. All these patients were
included at the time of AOSD diagnosis and were naïve for any4treatment. All these patients experienced fever (100%), 86.76%
of patients reported arthritis and 72.05% displayed typical skin
rash, respectively. The systemic score resulted to be 5.10±1.50.
No patient was affected, at the time of diagnosis, by life-
threatening AOSD manifestations. At baseline, inﬂammatory
markers and ferritin were increased (ESR: 61.11±26.58mm/
hour; CRP: 77.34±38.68mg/L; ferritin: 2544.73±367.34ng/
mL). Comparing 40 patients receiving high dosage of CCSs and
40 patients receiving low dosage of CCSs, no signiﬁcant
difference was observed in baseline clinical characteristics. These
ﬁndings are summarised in Table 1.3.2. Primary endpoint
In this study, the primary endpoint was assessed on 73 patients, 7
patients were excluded from this analysis. Speciﬁcally, 4 patients
developed MAS in the low dosage of CCSs group and 1 patient
was lost to follow-up, during the ﬁrst 6 months of observation. In
the high dosage of CCSs group, 1 patient developed MAS and 1
patient was lost to follow-up, during the ﬁrst 6 months of
observation. The clinical remission was achieved in 33 (45.20%)
patients in the ﬁrst phase of the study, as reported in Table 2.
Remarkably, 25 (64.79%) patients treated with the ﬁrst-line
treatment with high dosage of CCSs reached the primary
endpoint, a signiﬁcantly higher percentage when compared with
8 (22.85%) patients treated with the ﬁrst-line treatment with low
dosage of CCSs (P <.001). As detailed in Table 3, we also
observed that the ﬁrst-line treatment with high dosage of CCSs
was a strong predictor of primary endpoint achievement. In fact,
both univariate analysis (HR: 3.41; P: .014; CI 95%: 1.28–9.09)
and multivariate analysis (HR: 4.08; P: .008; CI 95%: 1.44–
11.57) showed that the ﬁrst-line treatment with high dosage of
CCSs was a signiﬁcant predictor of the achievement of the clinical
remission, during the ﬁrst 6 months of observation. In
multivariate analysis, selected clinical confounders (gender,
age, systemic score, ferritin, and CRP) did not result to be
signiﬁcantly associated with the primary endpoint. No signiﬁcant
multicollinearity between the selected variables was observed.3.3. Secondary endpoints
At the end of 18 months of follow-up, 17 (44.73%) patients
treated with the ﬁrst-line treatment with high dosage of CCSs
maintained the clinical remission, being classiﬁed as monocyclic
pattern, a signiﬁcant higher percentage when compared with 3
(8.57%) patients treated with the ﬁrst-line treatment with low
dosage of CCSs (P: .001), as reported in Table 2. We also
Table 3
Cox regression analyses assessing the ﬁrst-line therapy with high dosage of CCSs as predictor of the achievement of the remission in
AOSD patients, after 6 months of follow-up.
Remission HR SE P CI 95%
Univariate analysis assessing high dosage of CCSs as predictor of remission
High dosage CCSs 3.41 0.50 .014 1.28–9.09
Multivariate analysis assessing high dosage of CCSs as predictor of remission
High dosage CCSs 4.08 0.53 .008 1.44–11.57
Gender 1.16 0.51 .78 0.42–3.17
Age 1.01 0.01 .32 0.99–1.04
Systemic score 0.72 0.17 .06 0.52–1.04
Ferritin 1.01 0.01 .73 0.99–1.02
CRP 0.95 0.04 .28 0.94–1.03
Statistical signiﬁcance was expressed by a p value <.05. Bolded values indicate statistically signiﬁcant results. AOSD= adult onset Still’s disease, CCSs=corticosteroids; CRP=C reactive protein.
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was a strong predictor of this secondary endpoint achievement. In
fact, both univariate analysis (HR 5.12; P: .009; CI 95%: 1.51–
17.37) and multivariate analysis (HR: 6.91; P: .003; CI 95%:
1.89–25.24) showed that the ﬁrst-line treatment with high dosage
of CCSs was a signiﬁcant predictor of the achievement of the
monocyclic pattern, after 18 months as shown in Table 4. In
multivariate analysis, selected clinical confounders (gender, age,
systemic score, ferritin, and CRP) did not result to be signiﬁcantly
associated with this secondary endpoint. Concerning CCSs
discontinuation, in the high dosage of CCSs group, 13 (34.21%)
patients discontinued CCSs treatment, a higher percentage when
compared with 3 (10.35%) patients in the low dosage of CCSs
group (P: .03). Furthermore, we observed that ﬁrst-line treatment
with high dosage of CCSs was a strong predictor of the
achievement of the CCSs discontinuation. In fact, both univariate
analysis (HR 3.69; P: .042; CI 95%: 1.05–12.97) and
multivariate analysis (HR: 4.21; P: .033; CI 95%: 1.19–15.86)
showed that the ﬁrst-line treatment with high dosage of CCSs was
a signiﬁcant predictor of the achievement of the CCSs
discontinuation, after 18 months. The analysis of CCSs taperingTable 4
Cox regression analyses assessing the ﬁrst-line therapy with high dos
in AOSD patients and CCSs discontinuation, after 18 months of follo
Monocyclic pattern HR
Univariate analysis assessing high dosage of CCSs as predictor of monocyclic pattern
High dosage CCSs 5.12
Multivariate analysis assessing high dosage of CCSs as predictor of monocyclic pattern
High dosage CCSs 6.91
Gender 1.77
Age 1.09
Systemic score 0.76
Ferritin 1.01
CRP 0.99
CCSs discontinuation HR SE
Univariate analysis assessing high dosage of CCSs as predictor of CCSs discontinuation
High dosage CCSs 3.69
Multivariate analysis assessing high dosage of CCSs as predictor of CCSs discontinuation
High dosage CCSs 4.21
Gender 1.45
Age 1.05
Systemic score 0.84
Ferritin 1.01
CRP 0.99
Statistical signiﬁcance was expressed by a P value <.05. Bolded values indicate statistically signiﬁcan
5showed that, in our cohort, CCSs were usually tapered by the
reduction of 5mg prednisone-equivalent every 2 weeks until low-
dose was reached (5–10mg prednisone/day) or, where possible,
CCSs were discontinued.3.4. Additional endpoints
In our study, additional endpoints were assessed. Patients, where
appropriate, were assessed for MAS occurrence. We observed
that 4 (10.00%) patients developed MAS in the low dosage of
CCSs group, whereas 1 (2.50%) patient developed this
complication in the high dosage of CCSs group, Despite a
different trendwe did not observe a signiﬁcant difference between
the 2 groups (P: .16). These 5 patients were treated with iv CCSs
and cyclosporine with resolution of the complication. Finally, we
analyzed the clinical response in non-responder patients. These
were treated by the addition of MTX and/or biologic drugs to
CCSs. Forty patients were classiﬁed as non-responder after the
ﬁrst-line treatment with CCSs and were treated with MTX at
dosage of 10 to 15mg/week, in both groups of patients.
Administering therapeutic strategy with CCSs+MTX, 25age of CCSs as predictor of the achievement of monocyclic pattern
w-up.
SE P CI 95%
0.62 .009 1.51–17.37
0.66 .003 1.89–25.24
0.59 .34 0.57–5.62
0.01 .56 0.98–1.04
0.18 .14 0.54–1.08
0.01 .76 0.99–1.02
0.05 .11 0.98–1.01
P CI 95%
0.62 .042 1.05–12.97
0.64 .033 1.19–15.86
0.66 .57 0.39–5.28
0.17 .78 0.97–1.04
0.19 .36 0.57–1.22
0.01 .65 0.98–1.03
0.06 .41 0.98–1.06
t results. AOSD= adult onset Still’s disease, CCSs= corticosteroids; CRP=C reactive protein.
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(37.50%) patients needed to be further treated with combination
therapy CCSs+MTX+biologic drug. Speciﬁcally, 7 (46.67%)
patients of these biologic drug-treated patients received anakinra,
5 (40%) patients received TNFi (3 etanercept and 2 inﬂiximab)
and 3 (20%) patients received tocilizumab. The clinical remission
was observed in 10 (66.67%) patients treated with combination
therapy CCSs+MTX+biologic, during the follow-up.3.5. Safety
Concerning safety proﬁle in these studies, we analyzed data
reported in the clinical charts, 7% of enrolled patients’
experienced minor adverse events. No severe adverse events or
deaths were observed. The pattern of adverse events was
consistent with previous reports on CCSs, MTX, and biologic
drugs with no new signal identiﬁed.4. Discussion
In this study, we showed the effectiveness of the ﬁrst-line
treatment with high dosage of CCSs in inducing clinical remission
in naïve AOSD patients when compared with the ﬁrst-line
treatment with low dosage of CCSs. Interestingly, the ﬁrst-line
treatment with high dosage of CCSs was also associated with
achievement of monocyclic pattern and discontinuation of CCSs.
Furthermore, we observed the effectiveness of combination
therapies of CCSs with MTX and/or biologic drug in non-
responder patients.
We observed that a signiﬁcant percentage of patients treated
with the ﬁrst-line treatment with high dosage of CCSs achieved
the clinical remission at the end of the ﬁrst phase of evaluation,
conﬁrming that high dosages of CCSs could be more efﬁcient in
controlling the disease.[2,12] The effectiveness of CCSs is usually
reported within few days and the tapering should be started after
disappearance of symptoms and normalization of inﬂammatory
parameters.[28,29] Interestingly, the ﬁrst-line treatment with high
dosage of CCSs was also associated with the maintaining of
clinical remission, being a signiﬁcant predictor of the achievement
of the monocyclic pattern, after 18 months of follow-up. These
data could highlight the effectiveness of the ﬁrst-line treatment
with high dosage of CCSs in AOSD patients, suggesting the
clinical usefulness in inducing and maintaining remission in
AOSD. In fact, differently from previous studies in which 30% of
patients reached a clinical remission of the disease,[30–32] we
observed almost 60% of patients treated with the ﬁrst-line
treatment with high dosage of CCSs achieved the clinical
remission, after 6months. Furthermore, we observed that 44%of
these patients maintained the remission after 18 months of
follow-up, an increased percentage compared with patients
developing a chronic disease course in previous studies.[21,27,30–
32] Taking together, the results of our study could improve AOSD
management, the early administration of the treatment with high
dosage of CCSs could increase the achievement of clinical
remission and could reduce the development of chronic disease
course. Furthermore, the early suppression of the inﬂammatory
process could be also associated with the reduction of severe
AOSD-related complications, associated with high mortality
rate.[33–35] At the end of second phase of the study, we observed
that a signiﬁcant percentage of patients discontinued CCSs, after
ﬁst-line treatment with high dosage of CCSs. Considering that
CCSs dependency may occur until up 45% of AOSD
patients,[2,12,29] the possible discontinuation of CCSs, maintain-6ing the clinical response, could be a further improvement in
AOSD management.
In our study, we also assessed the effectiveness of combination
therapies in non-responder patients to the ﬁrst-line therapy with
CCSs. We reported clinical remission may be achieved adding
MTX to CCSs treatments. In fact, MTX is the most frequently
administered sDMARD in AOSD, for its CCSs-sparing effect,
and for clinical effectiveness.[24,36,37] The lack of clinical response
to ﬁrst-line CCSs and second-line sDMARDs could identify
refractory patients, although a validated deﬁnition of disease
activity is still missing in AOSD. In these patients, biologic agents
may be considered, as recently suggested by meta-analytic data
reporting the efﬁcacy of biologic drugs in AOSD.[38–40] In
accordance with these data, we observed clinical remission could
be achieved in non-responder patients by using a combination
therapy including CCSs, MTX, and biologic drugs, as reported in
available literature.[38–42]
Our work is affected by different limitations as observed in any
retrospective study and the results should be cautiously
interpreted. In general, a blinded randomized trial is regarded
as being less subject to any bias analyzing therapeutic strategy,
but it is not always feasible and difﬁcult to organize in a rare
disease in which carrying out prospective and adequately
powered studies is quite difﬁcult.[43–45] In this context, the
clinical usefulness of small case series and retrospective studies
could be suggested.[46–50] In addition, despite the achievement of
adequate number of patients according to our sample size
estimation, the retrospective selection of the comparator group
could also limit the external validity of our ﬁndings and future
studies are needed to entirely conﬁrm our results.
In conclusions, in this study, we showed the effectiveness of the
ﬁrst-line treatment with high dosage of CCSs in inducing clinical
remission in naïve AOSD patients when compared with the ﬁrst-
line treatment with low dosage of CCSs. Interestingly, the ﬁrst-
line treatment with high dosage of CCSs was also associated with
achievement of monocyclic pattern and discontinuation of CCSs.
Finally, we reported the effectiveness of combination therapies of
CCSs with MTX and/or biologic drug in non-responder patients.Acknowledgments
We thank Mrs Federica Sensini for her technical assistance.Author contributions
Conceptualization: Piero Ruscitti, Paola Cipriani, Giuliana
Guggino, Roberto Giacomelli.
Data curation: Piero Ruscitti, Paola Cipriani, Vasiliki Liakouli,
Giuliana Guggino, Francesco Carubbi, Berardicurti Onorina,
Francesco Ciccia, Roberto Giacomelli.
Formal analysis: Piero Ruscitti.
Investigation: Piero Ruscitti, Vasiliki Liakouli, Giuliana Gug-
gino, Francesco Carubbi, Berardicurti Onorina, Francesco
Ciccia, Roberto Giacomelli.
Methodology: Piero Ruscitti, Paola Cipriani, Roberto Giaco-
melli.
Project administration: Piero Ruscitti.
Resources: Piero Ruscitti.
Supervision: Piero Ruscitti, Paola Cipriani, Francesco Ciccia,
Roberto Giacomelli.
Validation: Piero Ruscitti, Paola Cipriani, Vasiliki Liakouli,
Giuliana Guggino, Francesco Carubbi, Berardicurti Onorina,
Francesco Ciccia, Roberto Giacomelli.
[21] Ruscitti P, Cipriani P, Masedu F, et al. Adult-onset Still’s disease:
Ruscitti et al. Medicine (2019) 98:15 www.md-journal.comVisualization: Piero Ruscitti, Paola Cipriani, Vasiliki Liakouli,
Giuliana Guggino, Francesco Carubbi, Berardicurti Onorina,
Francesco Ciccia, Roberto Giacomelli.
Writing – original draft: Piero Ruscitti, Roberto Giacomelli.
Writing – review & editing: Piero Ruscitti, Paola Cipriani,
Vasiliki Liakouli, Giuliana Guggino, Francesco Carubbi,
Berardicurti Onorina, Francesco Ciccia, Roberto Giacomelli.
Piero Ruscitti orcid: 0000-0003-3487-8551.References
[1] Ruscitti P, Giacomelli R. Pathogenesis of adult onset still’s disease:
current understanding and new insights. Expert Rev Clin Immunol
2018;14:965–76.
[2] Efthimiou P, Kadavath S, Mehta B. Life-threatening complications of
adult-onset Still’s disease. Clin Rheumatol 2014;33:305–14.
[3] Ruscitti P, Rago C, Breda L, et al. Macrophage activation syndrome in
Still’s disease: analysis of clinical characteristics and survival in paediatric
and adult patients. Clin Rheumatol 2017;36:2839–45.
[4] Ruscitti P, Cipriani P, Ciccia F, et al. Prognostic factors of macrophage
activation syndrome, at the time of diagnosis, in adult patients affected by
autoimmune disease: analysis of 41 cases collected in 2 rheumatologic
centers. Autoimmun Rev 2017;16:16–21.
[5] Ruscitti P, Cipriani P, Ciccia F, et al. H-ferritin and CD68(+) /H-ferritin
(+) monocytes/macrophages are increased in the skin of adult-onset Still’s
disease patients and correlate with the multi-visceral involvement of the
disease. Clin Exp Immunol 2016;186:30–8.
[6] Ruscitti P, Ciccia F, Cipriani P, et al. The CD68(+)/H-ferritin(+) cells
colonize the lymph nodes of the patients with adult onset Still’s disease
and are associated with increased extracellular level of H-ferritin in the
same tissue: correlation with disease severity and implication for
pathogenesis. Clin Exp Immunol 2016;183:397–404.
[7] Cush JJ, Medsger TAJr, Christy WC, et al. Adult-onset Still’s disease:
clinical course and outcome Arthritis Rheum 1987;30:186–94.
[8] Lebrun D, Mestrallet S, Dehoux M, et al. Validation of the Fautrel
classiﬁcation criteria for adult-onset Still’s disease. Semin Arthritis
Rheum 2018;47:578–85.
[9] Sfriso P, Priori R, Valesini G, et al. Adult-onset Still’s disease: an Italian
multicentre retrospective observational study of manifestations and
treatments in 245 patients. Clin Rheumatol 2016;35:1683–9.
[10] Castañeda S, Blanco R, González-Gay MA. Adult-onset Still’s disease:
advances in the treatment. Best PractResClinRheumatol 2016;30:222–38.
[11] Colafrancesco S, Priori R, Valesini G, et al. Response to interleukin-1
inhibitors in 140 Italian patients with Adult-onset Still’s disease: a
multicentre retrospective observational study. Front Pharmacol
2017;8:369. doi: 10.3389/fphar.2017.00369.
[12] Kong X-D, Xu D, Zhang W, et al. Clinical features and prognosis in
adult-onset Still’s disease: a study of 104 cases. Clin Rheumatol
2010;29:1015–114.
[13] Cipriani P, Ruscitti P, Carubbi F, et al. Tocilizumab for the treatment of
adult-onset Still’s disease: results from a case series. Clin Rheumatol
2014;33:49–55.
[14] Cipriani P, Ruscitti P, Carubbi F, et al. Methotrexate in rheumatoid
arthritis: optimizing therapy among different formulations. Current and
emerging paradigms. Clin Ther 2014;36:427–35.
[15] Maria AT, Le Quellec A, Jorgensen C, et al. Adult onset Still’s disease
(AOSD) in the era of biologic therapies: dichotomous view for cytokine
and clinical expressions. Autoimmun Rev 2014;13:1149–59.
[16] Kalyoncu U, Solmaz D, Emmungil H, et al. Response rate of initial
conventional treatments, disease course, and related factors of patients
with adult-onset Still’s disease: data from a large multicenter cohort. J
Autoimmun 2016;69:59–63.
[17] Landewé RB, Boers M, Verhoeven AC, et al. COBRA combination
therapy in patients with early rheumatoid arthritis: long-term structural
beneﬁts of a brief intervention. Arthritis Rheum 2002;46:347–56.
[18] van Tuyl LH, Boers M, Lems WF, et al. Survival, comorbidities and joint
damage 11 years after the COBRA combination therapy trial in early
rheumatoid arthritis. Ann Rheum Dis 2010;69:807–12.
[19] Markusse IM, Dirven L, Gerards AH, et al. Disease ﬂares in rheumatoid
arthritis are associated with joint damage progression and disability: 10-
year results from the BeSt study. Arthritis Res Ther 2015;17:232. doi:
10.1186/s13075-015-0730-2.
[20] Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for
classiﬁcation of adult Still’s disease. J Rheumatol 1992;19:424–30.7evaluation of prognostic tools and validation of the systemic score by
analysis of 100 cases from three centers. BMC Med 2016;14:194. doi.
10.1186/s12916-016-0738-8.
[22] Ruscitti P, Iacono D, Ciccia F, et al. Macrophage activation syndrome in
patients affected by adult onset Still’s disease: analysis of survival rate and
predictive factors inGIRRCS (Gruppo Italiano diRicerca inReumatologia
Clinica e Sperimentale) cohort. J Rheumatol J 2018;45:864–72.
[23] Chatzidionysiou K, Emamikia S, Nam J, et al. Efﬁcacy of glucocorticoids,
conventional and targeted synthetic disease-modifying antirheumatic
drugs: a systematic literature review informing the 2016 update of the
EULAR recommendations for the management of rheumatoid arthritis.
Ann Rheum Dis 2017;76:1102–7.
[24] Fautrel B, Borget C, Rozenberg S, et al. Corticosteroid sparing effect of
low dose methotrexate treatment in adult Still’s disease. J Rheumatol
1999;26:373–8.
[25] Pay S, Türkçapar N, Kalyoncu M, et al. A multicenter study of patients
with adult-onset Still’s disease compared with systemic juvenile
idiopathic arthritis. Clin Rheumatol 2006;25:639–44.
[26] Henter JI, Horne A, Aricó M, et al. HLH-2004: diagnostic and
therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr
Blood Cancer 2007;48:124–31.
[27] Pouchot J, Sampalis JS, Beaudet F, et al. Adult Still’s disease:
manifestations, disease course, and outcome in 62 patients. Medicine
(Baltimore) 1991;70:118–36.
[28] Jamilloux Y, Gerfaud-Valentin M, Henry T, et al. Treatment of adult-
onset Still’s disease: a review. Ther Clin Risk Manag 2014;11:33–43.
[29] Franchini S, Dagna L, Salvo F, et al. Efﬁcacy of traditional and biologic
agents in different clinical phenotypes of adult-onset Still’s disease.
Arthritis Rheum 2010;62:2530–5.
[30] Gerfaud-Valentin M, Maucort-Boulch D, Hot A, et al. Adult-onset still
disease: manifestations, treatment, outcome, and prognostic factors in 57
patients. Medicine (Baltimore) 2014;93:91–9.
[31] Kim YJ, Koo BS, Kim Y-G, et al. Clinical features and prognosis in 82
patients with adult-onset Still’s disease. Clin Exp Rheumatol
2013;32:28–33.
[32] ColinaM, ZucchiniW, Ciancio G, et al. The evolution of adult-onset Still
disease: an observational and comparative study in a cohort of 76 Italian
patients. Semin Arthritis Rheum 2011;41:279–85.
[33] Ruscitti P, Cipriani P, Di Benedetto P, et al. Advances in immunopatho-
genesis of macrophage activation syndrome during rheumatic inﬂam-
matory diseases: toward new therapeutic targets. Expert Rev Clin
Immunol 2017;13:1041–104.
[34] Ruscitti P, Cipriani P, Di Benedetto P, et al. H-ferritin and
proinﬂammatory cytokines are increased in the bone marrow of patients
affected by macrophage activation syndrome. Clin Exp Immunol
2018;19108:220–8.
[35] Ruscitti P, Cipriani P, Di Benedetto P, et al. Increased level of H-ferritin
and its imbalance with L-ferritin, in bone marrow and liver of patients
with adult onset Still’s disease, developing macrophage activation
syndrome, correlate with the severity of the disease. Autoimmun Rev
2015;14:429–37.
[36] Yoo DH. Treatment of adult-onset still’s disease: up to date. Expert Rev
Clin Immunol 2017;13:849–66.
[37] Zhou S, Qiao J, Bai J, et al. Biological therapy of traditional therapy-
resistant adult-onset Still’s disease: an evidence-based review. Ther Clin
Risk Manag 2018;14:167–71.
[38] Ruscitti P, Ursini F, Cipriani P, et al. Biologic drugs in adult onset Still’s
disease: a systematic review and meta-analysis of observational studies.
Expert Rev Clin Immunol 2017;13:1089–97.
[39] Hong D, Yang Z, Han S, et al. Interleukin 1 inhibition with anakinra in
adult-onset Still disease: a meta-analysis of its efﬁcacy and safety. Drug
Des Devel Ther 2014;8:2345–57.
[40] Ma Y, Wu M, Zhang X, et al. Efﬁcacy and safety of tocilizumab with
inhibition of interleukin-6 in adult-onset Still’s disease: A meta-analysis.
Mod Rheumatol 2018;1–9.
[41] Junge G, Mason J, Feist E. Adult onset Still’s disease-the evidence that
anti-interleukin-1 treatment is effective and well-tolerated (a compre-
hensive literature review). Semin Arthritis Rheum 2017;47:295–302.
[42] Kontzias A, Efthimiou P. The use of Canakinumab, a novel IL-1b long-
acting inhibitor, in refractory adult-onset Still’s disease. Semin Arthritis
Rheum 2012;42:201–5.
[43] Sun P, Garrison LP. Retrospective outcomes studies for orphan diseases:
challenges and opportunities. Curr Med Res Opin 2012;28:665–7.
[44] Guilpain P, Le Quellec A. About the complexity of adult onset Still’s
disease . . . and advances still required for its management. BMC Med
2017;15:5. doi: 10.1186/s12916-016-0769-1.
[45] Giacomelli R, Afeltra A, Alunno A, et al. International consensus: [47] Giacomelli R, Ruscitti P, Shoenfeld Y. A comprehensive review on adult
Ruscitti et al. Medicine (2019) 98:15 Medicinewhat else can we do to improve diagnosis and therapeutic
strategies in patients affected by autoimmune rheumatic diseases
(rheumatoid arthritis, spondyloarthritides, systemic sclerosis,
systemic lupus erythematosus, antiphospholipid syndrome and
Sjogren’s syndrome)?: the unmet needs and the clinical grey zone
in autoimmune disease management. Autoimmun Rev 2017;16:
911–24.
[46] Giampietro C, Ridene M, Lequerre T, et al. Anakinra in adult-onset
Still’s disease: long-term treatment in patients resistant to
conventional therapy. Arthritis Care Res (Hoboken) 2013;65:
822–6.8onset Still’s disease. J Autoimmun 2018;93:24–36.
[48] Néel A, Wahbi A, Tessoulin B, et al. Diagnostic and management of life-
threatening Adult-onset Still disease: a French nationwide multicenter
study and systematic literature review. Crit Care 2018;22:88. doi:
10.1186/s13054-018-2012-2.
[49] Kadavath S, Zapantis E, Zolty R, et al. A novel therapeutic approach in
pulmonary arterial hypertension as a complication of adult-onset Still’s
disease: targeting IL-6. Int J Rheum Dis 2014;17:336–409.
[50] Giacomelli R, Gorla R, Trotta F, et al. Quality of life and unmet needs in
patients with inﬂammatory arthropathies: results from the multicentre,
observational RAPSODIA study. Rheumatology (Oxf) 2015;54:792–7.
